Evolus, Inc. (NASDAQ:EOLS) Director Buys $204,600.00 in Stock

Key Points

• Brady Stewart, a director at Evolus, Inc., purchased 30,000 shares of stock for $204,600, increasing his position by 51.17% to a total of 88,629 shares.
• Evolus stock currently trades at $6.69, with a 52-week range of $5.71 to $17.82 and a market capitalization of approximately $432.71 million.
• Wall Street analysts have mixed opinions on Evolus, with a consensus average rating of "Moderate Buy" and a target price of $21.25, though some firms have recently reduced their price objectives.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Brady Stewart bought 30,000 shares of Evolus stock in a transaction dated Friday, August 15th. The stock was purchased at an average cost of $6.82 per share, with a total value of $204,600.00. Following the completion of the acquisition, the director directly owned 88,629 shares in the company, valued at approximately $604,449.78. The trade was a 51.17% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Evolus Price Performance

EOLS stock traded down $0.04 during trading on Monday, reaching $6.69. 987,321 shares of the company were exchanged, compared to its average volume of 1,106,926. The company has a debt-to-equity ratio of 22.00, a quick ratio of 1.86 and a current ratio of 2.27. The stock's 50 day moving average price is $8.89 and its 200 day moving average price is $10.82. Evolus, Inc. has a 52-week low of $5.71 and a 52-week high of $17.82. The company has a market cap of $432.71 million, a P/E ratio of -6.83 and a beta of 1.12.

Institutional Investors Weigh In On Evolus

Several institutional investors have recently modified their holdings of EOLS. Manchester Capital Management LLC purchased a new position in Evolus in the 2nd quarter valued at approximately $26,000. AlphaQuest LLC acquired a new position in shares of Evolus during the 1st quarter worth $39,000. State of Wyoming raised its stake in shares of Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after buying an additional 3,409 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company's stock worth $68,000 after buying an additional 5,691 shares in the last quarter. Finally, Profund Advisors LLC acquired a new stake in Evolus in the 2nd quarter valued at about $100,000. Hedge funds and other institutional investors own 90.69% of the company's stock.

Wall Street Analysts Forecast Growth

EOLS has been the subject of several research analyst reports. HC Wainwright decreased their price objective on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. BTIG Research lowered their price objective on shares of Evolus from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC reiterated a "hold" rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. Finally, Wall Street Zen cut Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Evolus currently has an average rating of "Moderate Buy" and a consensus target price of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.